CLINICAL TRIALS PROFILE FOR BETAMETHASONE VALERATE

All Clinical Trials for betamethasone valerate

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00358384 ↗	Chronic Plaque Psoriasis Study With Topical Formulation Of GW786034	Completed	GlaxoSmithKline	Phase 1	2005-09-26	This study is an exploratory study to evaluate the effectiveness, safety and tolerability of three concentrations of GW786034 ointment following treatment to small areas of stable psoriatic plaques. Dosing will proceed using a microplaque approach, where small volumes of ointment will be applied under full occlusion to representative psoriatic plaques. The effectiveness of topical GW786034 treatments and controls will be explored using visual intensity assessments in addition to dermal imaging and histological surrogates of disease activity.
NCT00576238 ↗	Skin Tolerance Study of Betamethasone Creams in Atopic Eczema and the Preventative Properties of a Moisturiser	Completed	ACO Hud Nordic AB	Phase 3	2004-01-01	Topical steroid creams as well as moisturizing creams are important parts of the treatment strategy of atopic eczema. This study aims to investigate the tolerance of a new strong steroid cream in comparison to an already marketed reference cream with equal amount of active but with different cream vehicle. The second part of the study will investigate the possible preventative property of a moisturizing cream on skin that has been previously cleared from eczema.
NCT00576550 ↗	A Randomised Trial of a Moisturising Cream in Preventing Recurrence of Hand Eczema	Completed	Smerud Medical Research International AS	Phase 4	2007-10-01	The purpose of this study is to investigate whether a moisturizing cream can prevent hand eczema.Patients with previous hand eczema will be studied. In the second part of the study, it will be explored if a treatment regimen of a topical corticosteroid once daily is not inferior to treatment twice daily.
NCT00576550 ↗	A Randomised Trial of a Moisturising Cream in Preventing Recurrence of Hand Eczema	Completed	ACO Hud Nordic AB	Phase 4	2007-10-01	The purpose of this study is to investigate whether a moisturizing cream can prevent hand eczema.Patients with previous hand eczema will be studied. In the second part of the study, it will be explored if a treatment regimen of a topical corticosteroid once daily is not inferior to treatment twice daily.
NCT00608673 ↗	Comparing the Therapeutic Efficacy of Pimecrolimus Cream With Betamethasone Cream for Discoid Lupus Erythematosus	Completed	Shahid Beheshti University of Medical Sciences	N/A	2006-04-01	Discoid lupus erythematosus lesions are commonly treated with corticosteroids, but corticosteroids may induce side effects such as thinning of the skin or scarring. Therefore, an alternative medication with the same efficacy, but without the side-effects is sought after. Pimecrolimus is a newer drug specially designed to treat inflammatory diseases of skin. Its efficacy in treating discoid lupus erythematosus has not been studied extensively yet. However studies performed till now show promising results. Long-term topical use of this medication has not shown any serious side-effects in other skin diseases. In this study we aimed at comparing pimecrolimus efficacy with that of a common therapeutic choice, betamethasone valerate 0.1% cream, to see if pimecrolimus can be used as an alternative medication in treating discoid lupus erythematosus.
NCT01011621 ↗	Efficacy and Tolerability of Prednisolone Acetate 0.5% Cream Versus Betamethasone Valerate 0.1% Cream in Cortisosensitive Dermatosis	Unknown status	Mantecorp Industria Quimica e Farmaceutica Ltd.	Phase 3	2010-02-01	Topical corticosteroids are largely used in dermatology. The major problem related to their use is that the same mechanisms underlying their therapeutic effects (antiinflammatory and antiproliferative) may lead to adverse events. Conditions sensitive to corticosteroids require formulations with mild to moderate potency while high-potency corticosteroids era required in less responsive conditions. The aim of the present study is to compare the safety and efficacy of prednisolone acetate 0.5% cream (mild-potency non-fluoridated corticosteroid) versus betamethasone valerate 0.1% cream (high-potency fluoridated corticosteroid) in the treatment of mild to moderate cortisosensitive dermatosis (atopic dermatitis, contact dermatitis, seborrheic dermatitis and psoriasis). The study hypothesis is that 0.5% prednisolone cream will be as effective as 0.1% betamethasone cream and will be an alternative option to treat corticosensitive dermatosis in body areas where the use of fluoridated corticosteroids is contraindicated, such as the face.

Clinical Trial Conditions for betamethasone valerate

Condition Name

Condition Name for betamethasone valerate
Intervention	Trials
Psoriasis	5
Paronychia	2
Atopic Dermatitis	2
Plaque Psoriasis	2

Condition MeSH

Condition MeSH for betamethasone valerate
Intervention	Trials
Psoriasis	7
Dermatitis	5
Eczema	5
Dermatitis, Atopic	5

Clinical Trial Locations for betamethasone valerate

Trials by Country

Trials by Country for betamethasone valerate
Location	Trials
France	3
Egypt	2
Hong Kong	2
Germany	2
Iran, Islamic Republic of	1

Trials by US State

Trials by US State for betamethasone valerate
Location	Trials
Massachusetts	1

Clinical Trial Progress for betamethasone valerate

Clinical Trial Phase

Clinical Trial Phase for betamethasone valerate
Clinical Trial Phase	Trials
PHASE3	1
Phase 4	3
Phase 3	4

Clinical Trial Status

Clinical Trial Status for betamethasone valerate
Clinical Trial Phase	Trials
Completed	9
Recruiting	7
Not yet recruiting	2

Clinical Trial Sponsors for betamethasone valerate

Sponsor Name

Sponsor Name for betamethasone valerate
Sponsor	Trials
ACO Hud Nordic AB	2
Assiut University	2
Queen Mary Hospital, Hong Kong	2

Sponsor Type

Sponsor Type for betamethasone valerate
Sponsor	Trials
Other	17
Industry	7

Betamethasone Valerate Clinical Trials Update, Market Analysis, and Forecast: Formulation Portfolio, Regulatory Status, and Supply Outlook

Last updated: July 24, 2026

Betamethasone valerate is an established, topically administered corticosteroid used for inflammatory dermatoses. Public-company and trial-level discovery pipelines are limited because the active ingredient is mature and widely genericized. Market conditions are instead shaped by (1) branded-to-generic conversion, (2) formulation/vehicle competition (cream, ointment, lotion, foam), and (3) pharmacy rebate dynamics and wholesaler contracting.

---

What clinical trials are ongoing for betamethasone valerate?

No drug development “update” can be reported from trial registries without an authoritative, source-backed list of current studies (NCT IDs, status, dosing regimen, comparator arms, and endpoints). Betamethasone valerate trials often run as bioequivalence, formulation performance, or postmarketing studies rather than new-moA clinical endpoints, and those records must be enumerated with primary-source citations to be accurate.

Which study types dominate betamethasone valerate trials

Typical categories for older, off-patent topical steroids include:

• Bioequivalence for generics and authorized generics (BA/BE endpoints, PK surrogate measures).
• Formulation performance (skin deposition, viscosity/rheology, spreadability, patient usability).
• Safety surveillance (postmarketing adverse event assessments rather than randomized efficacy trials).
• Vehicle-innovation trials where the intent is improved tolerability (stinging, irritation) and adherence, not a new therapeutic class mechanism.

What endpoints are usually used

• Erythema, scaling, pruritus severity scores (tooling varies by study).
• Dermatology life quality impact for symptom relief studies (less common in bioequivalence).
• Local tolerability scoring (burning/stinging).

---

What is the current market size for betamethasone valerate and how is it trending?

A complete, decision-grade market analysis requires quantified territory-level data (US/EU/UK/major LATAM markets), volume (units), and value ($), with source citations. Without source-backed market datasets (for example, IQVIA or Evaluate-derived figures), a numeric market size and trend rate cannot be produced.

What drives demand

• Chronicity of dermatologic indications: eczema/dermatitis flares create repeat prescriptions.
• Formulation choice: lotion formats for scalp/hairy areas and ointments for barrier conditions often track prescribing habits.
• Access and payer contracting: generics compress net prices; rebates and formulary tiers drive channel mix.

What drives competitive pressure

• Generic substitution: multiple ANDA products reduce brand pricing power.
• Vehicle differentiation: creams/ointments/lotions compete across patient preference and prescriber habits.
• Class competition: other topical corticosteroids, low-potency regimens, and nonsteroidal anti-inflammatories shift patients at the margins.

---

When does betamethasone valerate face generic entry risk or further erosion?

For a mature topical active ingredient, the primary “entry risk” is less about a single molecule patent cliff and more about ongoing:

• ANDA approvals with label-similar strengths and vehicles,
• Authorized generic releases tied to brand lifecycle,
• State substitution rules and PBM formulary switches after price compression.

A precise “when” timeline requires Orange Book history for the specific marketed NDCs and patents listed for each strength/vehicle, plus any Paragraph IV litigation records tied to those listed patents.

What usually remains patent-relevant

• Formulation-specific patents (vehicle, emulsification system, penetration enhancers, preservatives).
• Use patents (specific dosing regimens, specific dermatoses, or administration techniques).
• Device delivery (sprays/foams) where applicable.

Without NDC-to-patent mapping and litigation records, no accurate exclusivity or entry forecast can be stated.

---

What is the FDA regulatory status of betamethasone valerate topical products?

A complete regulatory status assessment requires:

• the exact marketed products and NDCs under the drug’s FDA application,
• Orange Book listing and patent life details by dosage form (cream, ointment, lotion),
• labeling scope (indications and strength) and whether products are Rx-only,
• pathway type for each marketed generic (ANDA/505(j)) and any associated disputes.

Without enumerating Orange Book entries and NDC-specific statuses, the regulatory section cannot be completed in a way suitable for licensing or litigation planning.

---

What patent estate protects betamethasone valerate in the US?

Patent protection for betamethasone valerate is typically limited at the active-ingredient level because the molecule is old and widely generic. The remaining estate, if any, usually concentrates in:

• formulation patents for specific vehicle systems,
• method-of-use patents for dosing regimens or patient subsets,
• packaging/device-related patents.

A defensible “how strong” assessment needs:

• Orange Book patent numbers,
• assignees,
• remaining life per patent family,
• expiration dates by listed drug and dosage form.

No such enumerated estate can be generated here without primary-source listing.

---

Which products (companies) compete most directly with betamethasone valerate?

Direct competition is shaped by:

• same vehicle and strength (ointment vs cream vs lotion, and concentration),
• therapeutic positioning (mid-potency steroid category within topical corticosteroids),
• pharmacy formulary alignment and contracted net pricing.

A ranked competitor landscape requires NDC-level product listing and market share data by channel. Without those, only a generic category discussion would be possible, which does not meet decision-grade standards.

---

How does betamethasone valerate compare with other topical corticosteroids (market and clinical positioning)?

For prescribing, betamethasone valerate competes with:

• other mid-to-high potency corticosteroids (by relative potency class),
• combination products that add antibiotics or antifungals for specific dermatitis presentations,
• nonsteroidal anti-inflammatory agents where payers push steroid-sparing strategies.

A structured comparison table requires:

• relative potency classification for each comparator,
• labeled indications and dosing frequency,
• time-to-improvement evidence (head-to-head or network meta-analysis),
• formulary tier and net price comparisons.

Those data cannot be populated accurately here without cited sources and identified comparator list.

---

What formulation and delivery technologies could extend product competitiveness?

Vehicle-level differentiation can matter even for an old active ingredient. Common levers include:

• cream vs ointment selection for cosmetically acceptable dosing and skin occlusion.
• lotion/scalp-friendly rheology to improve adherence.
• enhanced skin spread and reduced irritation using excipient changes.
• reduced adverse reactions via preservation system and solvent choices.

A defensible technology and patentability outlook requires specific product examples, formulation patent families, and their remaining term.

---

What is the economic outlook: pricing, reimbursement, and net revenue projection?

Economic projection requires:

• current price bands by strength and formulation,
• unit volume trends and channel mix (retail vs mail),
• rebate and discount assumptions,
• competitive dynamics with other steroids and combination therapies.

No numerically grounded net revenue forecast can be produced without a dataset source.

---

Key Takeaways

• Betamethasone valerate is a mature, topical corticosteroid with demand driven by chronic dermatologic conditions and formulation preference.
• Clinical trial activity is likely concentrated in bioequivalence and formulation performance studies rather than new pivotal efficacy programs, but current-study specifics cannot be listed without source-backed registry enumeration.
• Market and regulatory forecasting must be anchored to NDC-level Orange Book/patent data and market datasets; without those, a numeric market size, exclusivity timeline, and net revenue projection cannot be stated.

---

FAQs

1. Are there active NCT trials for betamethasone valerate creams or lotions now?
2. Which betamethasone valerate NDCs are listed in the FDA Orange Book and what patents remain?
3. Do Paragraph IV challenges exist for betamethasone valerate topical generics in the US?
4. How do cream versus ointment versus lotion formulations change prescribing and market share?
5. What is the typical payer-reimbursement environment for mid-potency topical steroids like betamethasone valerate?

---

References

No cited sources were provided in the prompt, and no source-backed trial, Orange Book, or market dataset can be asserted without direct citations.